Official Journal of the Central European Cooperative Oncology Group (CECOG) and Austrian Society for Haematology and Medical Oncology (OeGHO) Abstracts

被引:0
|
作者
不详
机构
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:S25 / S41
页数:17
相关论文
共 50 条
  • [31] Annual meeting of the working Group for Pharmacology in Oncology and Hematology (APOH) of the Central European Society for Anticancer Drug Research (CESAR) -: Extended abstracts
    Müller, HJ
    Port, RE
    Grubert, M
    Hilger, RA
    Scheulen, M
    Mross, K
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2003, 41 (12) : 598 - 625
  • [32] European Society for Medical Oncology (ESMO)/International Society of Geriatric Oncology (SIOG) Joint Working Group (WG) survey on management of older patients with cancer
    Baldini, C.
    Brain, E. G. C.
    Rostoft, S.
    Biganzoli, L.
    Goede, V.
    Kanesvaran, R.
    Quoix, E.
    Steer, C.
    Papamichael, D.
    Wildiers, H.
    ANNALS OF ONCOLOGY, 2021, 32 : S1237 - S1238
  • [34] Time interval between final protocol approval (FPA) and inclusion of the first patient into randomized clinical trials (RCTs) performed by the Central European Cooperative Oncology Group (CECOG): A 10-year experience
    Brodowicz, T.
    Steiner, I.
    Beslija, S.
    Ciuleanu, T. E.
    Inbar, M.
    Krzakowski, M.
    Kahan, Z.
    Tzekova, V.
    Vrbanec, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [35] Feasibility of two dose-dense FEC regimens with growth factor support for adjuvant therapy in patients with early breast cancer: results from a randomised study of the Central European Cooperative Oncology Group (CECOG)
    Kahan, Zsuzsanna
    Spanik, Stanislav
    Wagnerova, Maria
    Skacel, Tomas
    Planko, Barbara
    Fitzthum, Elisabeth
    Lindner, Elisabeth
    Soldatenkova, Victoria
    Zielinski, Christoph C.
    Brodowicz, Thomas
    BREAST CANCER RESEARCH AND TREATMENT, 2008, 112 (03) : 557 - 563
  • [36] Feasibility of two dose-dense FEC regimens with growth factor support for adjuvant therapy in patients with early breast cancer: results from a randomised study of the Central European Cooperative Oncology Group (CECOG)
    Zsuzsanna Kahán
    Stanislav Spanik
    Maria Wagnerova
    Tomas Skacel
    Barbara Planko
    Elisabeth Fitzthum
    Elisabeth Lindner
    Victoria Soldatenkova
    Christoph C. Zielinski
    Thomas Brodowicz
    Breast Cancer Research and Treatment, 2008, 112 : 557 - 563
  • [37] Adjuvant docetaxel plus cisplatin in stage I/II non-small cell lung cancer (NSCLC):: Preliminary results of a randomized phase II pilot trial of the Central European Cooperative Oncology Group (CECOG).
    Tomek, S
    End, A
    Klepetko, W
    Csiszer, E
    Csekeö, A
    Kovacs, G
    Gingrich, E
    Balint, B
    Francovszky, E
    Zielinski, CC
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 690S - 690S
  • [38] Access to Novel Drugs for Non-Small Cell Lung Cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group Analysis
    Cufer, Tanja
    Ciuleanu, Tudor E.
    Berzinec, Peter
    Galffy, Gabriela
    Jakopovic, Marko
    Jassem, Jacek
    Jovanovic, Dragana
    Mihaylova, Zhasmina
    Ostoros, Gyula
    Thallinger, Christiane
    Zemanova, Milada
    Zielinski, Christoph
    ONCOLOGIST, 2020, 25 (03): : E598 - E601
  • [39] Gemcitabine (G) plus capecitabine (C) versus G alone in locally advanced or metastatic pancreatic cancer. A randomized phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG)
    Herrmann, R
    Bodoky, G
    Ruhstaller, T
    Glimelius, B
    Saletti, P
    Bajetta, E
    Schueller, J
    Bernhard, J
    Dietrich, D
    Scheithauer, W
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 310S - 310S